New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination

The COVID‐19 mRNA vaccines not only provide remarkable protection but also have been characterized by an overall safe and well‐tolerated side effect profile. Herein, we discuss a rare but manageable cutaneous reaction to COVID vaccination in order to further characterize dermatologic reactions and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaminetsky, Joshua, Rudikoff, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465924/
https://www.ncbi.nlm.nih.gov/pubmed/34603727
http://dx.doi.org/10.1002/ccr3.4865
_version_ 1784573000973025280
author Kaminetsky, Joshua
Rudikoff, Donald
author_facet Kaminetsky, Joshua
Rudikoff, Donald
author_sort Kaminetsky, Joshua
collection PubMed
description The COVID‐19 mRNA vaccines not only provide remarkable protection but also have been characterized by an overall safe and well‐tolerated side effect profile. Herein, we discuss a rare but manageable cutaneous reaction to COVID vaccination in order to further characterize dermatologic reactions and stress the continued vaccination of eligible patients.
format Online
Article
Text
id pubmed-8465924
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84659242021-10-01 New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination Kaminetsky, Joshua Rudikoff, Donald Clin Case Rep Case Report The COVID‐19 mRNA vaccines not only provide remarkable protection but also have been characterized by an overall safe and well‐tolerated side effect profile. Herein, we discuss a rare but manageable cutaneous reaction to COVID vaccination in order to further characterize dermatologic reactions and stress the continued vaccination of eligible patients. John Wiley and Sons Inc. 2021-09-26 /pmc/articles/PMC8465924/ /pubmed/34603727 http://dx.doi.org/10.1002/ccr3.4865 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kaminetsky, Joshua
Rudikoff, Donald
New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
title New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
title_full New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
title_fullStr New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
title_full_unstemmed New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
title_short New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
title_sort new‐onset vitiligo following mrna‐1273 (moderna) covid‐19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465924/
https://www.ncbi.nlm.nih.gov/pubmed/34603727
http://dx.doi.org/10.1002/ccr3.4865
work_keys_str_mv AT kaminetskyjoshua newonsetvitiligofollowingmrna1273modernacovid19vaccination
AT rudikoffdonald newonsetvitiligofollowingmrna1273modernacovid19vaccination

Ejemplares similares